Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma

Ronald Levy; Kristen N. Ganjoo; John P. Leonard; Julie M. Vose; Ian W. Flinn; Richard F. Ambinder; Joseph M. Connors; Neil L. Berinstein; Andrew R. Belch; Nancy L. Bartlett; Craig Nichols; Christos E. Emmanouilides; John M. Timmerman; Stephanie A. Gregory; Brian K. Link; David J. Inwards; Arnold S. Freedman; Jeffrey V. Matous; Michael J. Robertson; Lori A. Kunkel; Diane E. Ingolia; Andrew J. Gentles; Chih Long Liu; Robert Tibshirani; Ash A. Alizadeh; Dan W. Denney

doi:10.1200/JCO.2012.43.9273

Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma

Ronald Levy
, Kristen N. Ganjoo
, John P. Leonard
, Julie M. Vose
, Ian W. Flinn
, Richard F. Ambinder
, Joseph M. Connors
, Neil L. Berinstein
, Andrew R. Belch
, Nancy L. Bartlett
, Craig Nichols
, Christos E. Emmanouilides
, John M. Timmerman
, Stephanie A. Gregory
, Brian K. Link
, David J. Inwards
, Arnold S. Freedman
, Jeffrey V. Matous
, Michael J. Robertson
, Lori A. Kunkel

Diane E. Ingolia, Andrew J. Gentles, Chih Long Liu, Robert Tibshirani, Ash A. Alizadeh, Dan W. Denney

Stanford University
Genitope
Cornell University
Oncology/Hematology
Johns Hopkins University
University of British Columbia
University of Toronto
Cross Cancer Institute
Washington University in St. Louis
Oregon Health & Science University
University of California, Los Angeles
Rush University Medical Center
University of Iowa
Mayo Clinic
Harvard University
Rocky Mountain Cancer Centers
Indiana University – Purdue University Indianapolis

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	32
Issue number	17
DOIs	https://doi.org/10.1200/JCO.2012.43.9273
State	Published - Jun 10 2014
Externally published	Yes

Disciplines

Immunology and Infectious Disease
Medicine and Health Sciences

Access to Document

10.1200/JCO.2012.43.9273License: Unspecified

Cite this

Levy, R., Ganjoo, K. N., Leonard, J. P., Vose, J. M., Flinn, I. W., Ambinder, R. F., Connors, J. M., Berinstein, N. L., Belch, A. R., Bartlett, N. L., Nichols, C., Emmanouilides, C. E., Timmerman, J. M., Gregory, S. A., Link, B. K., Inwards, D. J., Freedman, A. S., Matous, J. V., Robertson, M. J., ... Denney, D. W. (2014). Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma. Journal of Clinical Oncology, 32(17). https://doi.org/10.1200/JCO.2012.43.9273

Levy, R, Ganjoo, KN, Leonard, JP, Vose, JM, Flinn, IW, Ambinder, RF, Connors, JM, Berinstein, NL, Belch, AR, Bartlett, NL, Nichols, C, Emmanouilides, CE, Timmerman, JM, Gregory, SA, Link, BK, Inwards, DJ, Freedman, AS, Matous, JV, Robertson, MJ, Kunkel, LA, Ingolia, DE, Gentles, AJ, Liu, CL, Tibshirani, R, Alizadeh, AA & Denney, DW 2014, 'Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma', Journal of Clinical Oncology, vol. 32, no. 17. https://doi.org/10.1200/JCO.2012.43.9273

@article{2ee824694355482e901599d5742e4aa5,

title = "Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma",

author = "Ronald Levy and Ganjoo, \{Kristen N.\} and Leonard, \{John P.\} and Vose, \{Julie M.\} and Flinn, \{Ian W.\} and Ambinder, \{Richard F.\} and Connors, \{Joseph M.\} and Berinstein, \{Neil L.\} and Belch, \{Andrew R.\} and Bartlett, \{Nancy L.\} and Craig Nichols and Emmanouilides, \{Christos E.\} and Timmerman, \{John M.\} and Gregory, \{Stephanie A.\} and Link, \{Brian K.\} and Inwards, \{David J.\} and Freedman, \{Arnold S.\} and Matous, \{Jeffrey V.\} and Robertson, \{Michael J.\} and Kunkel, \{Lori A.\} and Ingolia, \{Diane E.\} and Gentles, \{Andrew J.\} and Liu, \{Chih Long\} and Robert Tibshirani and Alizadeh, \{Ash A.\} and Denney, \{Dan W.\}",

note = "Purpose Idiotypes (Ids), the unique portions of tumor immunoglobulins, can serve as targets for passive and active immunotherapies for lymphoma. We performed a multicenter, randomized trial comparing a specific vaccine (MyVax), comprising Id chemically coupled to keyhole limpet hemocyanin (KLH) plus granulocyte macrophage colony-stimulating factor (GM-CSF) to a control immunotherapy with KLH plus GM-CSF.",

year = "2014",

month = jun,

day = "10",

doi = "10.1200/JCO.2012.43.9273",

language = "American English",

volume = "32",

journal = "Journal of Clinical Oncology",

number = "17",

}

TY - JOUR

T1 - Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma

AU - Levy, Ronald

AU - Ganjoo, Kristen N.

AU - Leonard, John P.

AU - Vose, Julie M.

AU - Flinn, Ian W.

AU - Ambinder, Richard F.

AU - Connors, Joseph M.

AU - Berinstein, Neil L.

AU - Belch, Andrew R.

AU - Bartlett, Nancy L.

AU - Nichols, Craig

AU - Emmanouilides, Christos E.

AU - Timmerman, John M.

AU - Gregory, Stephanie A.

AU - Link, Brian K.

AU - Inwards, David J.

AU - Freedman, Arnold S.

AU - Matous, Jeffrey V.

AU - Robertson, Michael J.

AU - Kunkel, Lori A.

AU - Ingolia, Diane E.

AU - Gentles, Andrew J.

AU - Liu, Chih Long

AU - Tibshirani, Robert

AU - Alizadeh, Ash A.

AU - Denney, Dan W.

N1 - Purpose Idiotypes (Ids), the unique portions of tumor immunoglobulins, can serve as targets for passive and active immunotherapies for lymphoma. We performed a multicenter, randomized trial comparing a specific vaccine (MyVax), comprising Id chemically coupled to keyhole limpet hemocyanin (KLH) plus granulocyte macrophage colony-stimulating factor (GM-CSF) to a control immunotherapy with KLH plus GM-CSF.

PY - 2014/6/10

Y1 - 2014/6/10

UR - https://ascopubs.org/doi/pdf/10.1200/JCO.2012.43.9273

U2 - 10.1200/JCO.2012.43.9273

DO - 10.1200/JCO.2012.43.9273

M3 - Article

VL - 32

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 17

ER -

Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma

Disciplines

Access to Document

Other files and links

Cite this